(function(){ var content_array=["
關于濟民可信集團<\/strong><\/p> \n 濟民可信集團創建于1999年,總部位于中國南昌,主要產品管線為腎病、腫瘤、心腦血管、呼吸抗感染、疼痛五大領域,致力于為患者提供高質量的藥品和創新醫藥解決方案。作為中國領先的大型現代制藥集團之一,濟民可信集團已連續多年位列中國醫藥工業百強前十。<\/p> \n 參考文獻<\/strong><\/p> \n [1] Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China<\/span>: a national cross-sectional study[J]. Lancet, 2019, 394(10196): 407-418. <\/sup> <\/p> \n
[2] Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program[J]. J Allergy Clin Immunol, 2007,119(2):405-413.<\/sup><\/p> \n